Hepatitis B surface antigen (HBsAg) levels in the natural history of hepatitis B virus (HBV)-infection: A European perspective

被引:349
作者
Jaroszewicz, Jerzy [1 ,2 ]
Serrano, Beatriz Calle [1 ]
Wursthorn, Karsten [1 ]
Deterding, Katja [1 ]
Schlue, Jerome [3 ]
Raupach, Regina [1 ]
Flisiak, Robert [2 ]
Bock, C. -Thomas [4 ,5 ]
Manns, Michael P. [1 ]
Wedemeyer, Heiner [1 ]
Cornberg, Markus [1 ]
机构
[1] Hannover Med Sch, Dept Gastroenterol Hepatol & Endocrinol, D-30625 Hannover, Germany
[2] Med Univ Bialystok, Dept Infect Dis & Hepatol, Bialystok, Poland
[3] Hannover Med Sch, Dept Pathol, D-30625 Hannover, Germany
[4] Robert Koch Inst, Dept Infect Dis, D-1000 Berlin, Germany
[5] Univ Tubingen Hosp, Dept Mol Pathol, Tubingen, Germany
关键词
Hepatitis B virus; HBsAg; Chronic hepatitis B; HBV-genotype; HBV-DNA; PEGINTERFERON ALPHA-2A; SERUM HBSAG; HBV DNA; HBEAG; DECLINE; LIVER; QUANTITATION; COMBINATION; LAMIVUDINE; INFECTION;
D O I
10.1016/j.jhep.2010.01.014
中图分类号
R57 [消化系及腹部疾病];
学科分类号
摘要
Background & Aims: The quantifiable level of HBsAg has been suggested as a predictor of treatment response in chronic hepatitis B. However, there is limited information on HBsAg levels considering the dynamic natural course of HBV-infection. This study aimed to determine HBsAg levels in the different phases of HBV-infection in European HBsAg-positive patients. Methods: 226 HBV-monoinfected patients, not undergoing antiviral therapy, were analyzed in a cross-sectional study. Patients were categorized according to the phase of HBV-infection: HBeAg(+) immune tolerance phase (IT, n = 30), immune clearance phase (IC, n = 48), HBeAg(-) low-replicative phase (LR, n = 68), HBeAg(-) hepatitis (ENH, n = 68), and acute hepatitis B (n = 12). HBsAg was quantified and correlated with HBV-DNA, HBV-genotypes and clinical parameters. In addition, 30 LR-patients were followed longitudinally. Results: HBsAg levels were higher in IT-patients and IC-patients compared to LR-patients and ENH-patients (4.96/4.37/3.09/3.87-log(10) IU/ml, p < 0.001). HBsAg showed a strong correlation with HBV-DNA during acute hepatitis B (R = 0.79, p < 0.01). Correlation of HBsAg and HBV-DNA was weak or missing when analyzing different phases of persistent HBV-infection separately. However, associations between HBsAg and HBV-DNA were observed in patients infected with HBV-genotype D but not with HBV-genotype A. LR-patients with HBV-reactivation during follow-up (increase of HBV-DNA > 2000 IU/ml) showed > 3-fold higher baseline HBsAg levels with a NPV of 95% for an HBsAg cut-off of 3500 IU/ml. Conclusions: HBsAg levels show significant differences during the natural course of HBV-infection and between HBV-genotypes. These findings may have important implications for understanding the natural history of HBV-infection and for using quantitative HBsAg as a diagnostic tool, i.e. as a marker for predicting HBV-reactivation. (c) 2010 European Association for the Study of the Liver. Published by Elsevier B.V. All rights reserved.
引用
收藏
页码:514 / 522
页数:9
相关论文
共 41 条
  • [1] Tumor necrosis factor alpha inhibition of hepatitis B virus replication involves disruption of capsid integrity through activation of NF-κB
    Biermer, M
    Puro, R
    Schneider, RJ
    [J]. JOURNAL OF VIROLOGY, 2003, 77 (07) : 4033 - 4042
  • [2] Genomic DNA double-strand breaks are targets for hepadnaviral DNA integration
    Bill, CA
    Summers, J
    [J]. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 2004, 101 (30) : 11135 - 11140
  • [3] A NEW ANTIGEN IN LEUKEMIA SERA
    BLUMBERG, BS
    ALTER, HJ
    VISNICH, S
    [J]. JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 1965, 191 (07): : 541 - &
  • [4] Clearance of Serum HBsAg and Anti-HBs Seroconversion Following Antiviral Therapy for Chronic Hepatitis B
    Borgniet, Olivier
    Parvaz, Parviz
    Bouix, Cecile
    Chevallier, Philippe
    Trepo, Christian
    Andre, Patrice
    Zoulim, Fabien
    [J]. JOURNAL OF MEDICAL VIROLOGY, 2009, 81 (08) : 1336 - 1342
  • [5] Hepatitis B Virus Surface Antigen Levels: A Guide to Sustained Response to peginterferon alfa-2a in HBeAg-Negative Chronic Hepatitis B
    Brunetto, Maurizia Rossana
    Moriconi, Francesco
    Bonino, Ferruccio
    Lau, George K. K.
    Farci, Patrizia
    Yurdaydin, Cihan
    Piratvisuth, Teerha
    Luo, Kanxian
    Wang, Yuming
    Hadziyannis, Stephanos
    Wolf, Eva
    McCloud, Philip
    Batrla, Richard
    Marcellin, Patrick
    [J]. HEPATOLOGY, 2009, 49 (04) : 1141 - 1150
  • [6] Peginterferon alpha-2b is safe and effective in HBeAg-positive chronic hepatitis B patients with advanced fibrosis
    Buster, Erik H. C. J.
    Hansen, Bettina E.
    Buti, Maria
    Delwaide, Jean
    Niederau, Claus
    Michielsen, Peter P.
    Flisiak, Robert
    Zondervan, Pieter E.
    Schalm, Solko W.
    Janssen, Harry L. A.
    [J]. HEPATOLOGY, 2007, 46 (02) : 388 - 394
  • [7] Serum hepatitis B surface antigen quantitation can reflect hepatitis B virus in the liver and predict treatment response
    Chan, Henry Lik-Yuen
    Wong, Vincent Wai-Sun
    Tse, Ada Mei-Ling
    Tse, Chi-Hang
    Chim, Angel Mei-Ling
    Chan, Hoi-Yun
    Wong, Grace Lai-Hung
    Sung, Joseph Jao-Yiu
    [J]. CLINICAL GASTROENTEROLOGY AND HEPATOLOGY, 2007, 5 (12) : 1462 - 1468
  • [8] CHEMIN I, 2009, CANC LETT 0113
  • [9] The German guideline for the management of hepatitis B virus infection: short version
    Cornberg, M.
    Protzer, U.
    Dollinger, M. M.
    Petersen, J.
    Wedemeyer, H.
    Berg, T.
    Jilg, W.
    Erhardt, A.
    Wirth, S.
    Schirmacher, P.
    Fleig, W. E.
    Manns, M. P.
    [J]. JOURNAL OF VIRAL HEPATITIS, 2008, 15 : 1 - 21
  • [10] Quantitation of hepatitis B surface antigen by an automated chemiluminescent microparticle immunoassay
    Deguchi, M
    Yamashita, N
    Kagita, M
    Asari, S
    Iwatani, Y
    Tsuchida, T
    Iinuma, K
    Mushahwar, IK
    [J]. JOURNAL OF VIROLOGICAL METHODS, 2004, 115 (02) : 217 - 222